CVS Health exceeded analysts' expectations for the second quarter, reporting adjusted earnings per share of $2.58 compared to the anticipated $1.85, and revenue of $106.10 billion versus the expected $100.11 billion. The company raised its full-year adjusted profit guidance to between $7.90 and $8.10 per share, up from a previous range of $7.30 to $7.50.
CVS also projected revenue of at least $414 billion for 2026, an increase from its prior estimate of $405 billion. The growth in profit guidance is attributed to improvements in both the insurance and retail pharmacy segments, although CVS maintains a cautious outlook due to high medical costs and economic uncertainties. Shares rose 1% in premarket trading following the announcement.
All three business segments—insurance, pharmacy, and health services—outperformed Wall Street's revenue expectations. Aetna's performance is particularly noteworthy, as its medical benefit ratio improved to 87.4%, indicating better management of medical costs compared to the previous year. The insurance unit generated $37.54 billion in revenue, surpassing analyst expectations of $35.66 billion.
CVS also announced a collaboration with Eli Lilly to make obesity treatments accessible through its health app, further enhancing its service offerings. Overall, CVS's results signal a positive trend in its turnaround strategy, which includes cost-cutting measures and operational adjustments